1. Introduction {#sec1}
===============

Contrast-induced acute kidney injury (CI-AKI) is a common and serious complication after cardiac catheterization (CC), percutaneous coronary intervention (PCI), and coronary angiography (CAG). It accounts for 12% of all hospital-acquired kidney failure and increases the length of hospitalization, a situation that is worsening with increasing numbers of patients with comorbidities, including those requiring cardiovascular interventional procedures \[[@B1]\]. Unfortunately, current preventive methods for CI-AKI are limited and often ineffective \[[@B2]\]. Thus, the early and effective diagnosis of CI-AKI is important. Currently, the concentration of serum creatinine (sCr) is the most commonly accepted clinical standard for diagnosis of CI-AKI and it has several limitations. For example, sCR is affected by many factors (e.g., age, sex, race, weight, and drugs) \[[@B3]\]. Moreover, it takes over 24 to 48 hours to diagnose CI-AKI using sCr, which makes it too late for intervention \[[@B4]\]. Thus, sCr is believed to be inadequate for the diagnosis of CI-AKI, and there is an urgent need for biomarkers that can detect CI-AKI sooner and more accurately.

Kidney injury molecule 1 (KIM-1) is a phosphatidylserine receptor that is expressed in epithelial cells. It enables epithelial cells to recognize and phagocytose dead cells that are present in the stressed kidney \[[@B5]\]. KIM-1 is undetectable in the urine of normal subjects \[[@B6]\]. However, following renal tubular injury, KIM-1 is upregulated and delivered into the extracellular space and the urine, making it possible to detect renal damage \[[@B6], [@B7]\]. Previous reports have demonstrated that KIM-1 is an excellent predictor of proximal tubular injury compared with sCr in rats \[[@B7]\]. Several human studies have also shown that urinary KIM-1 (uKIM-1) can be detected well before the increase of sCr, thus making it a sensitive and specific early biomarker of CI-AKI \[[@B8]--[@B10]\]. Recently, reviews have shown that uKIM-1 is a promising biomarker for the diagnosis of acute kidney injury (AKI) \[[@B1], [@B11]\]. However, the predicative value of uKIM-1 for CI-AKI after percutaneous coronary intervention (PCI) or coronary angiography (CAG) still remains to be established. This meta-analysis was conducted to determine the predictive ability of uKIM-1 for the diagnosis of CI-AKI following PCI or CAG based on research evidence currently available.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

This meta-analysis was performed according to the guideline of PRISMA statement \[[@B12]\]. Relevant articles were identified through a systematic search of PubMed, Medline, Embase, Cochrane Library, ClinicalTrials.gov, and the China National Knowledge Infrastructure (CNKI) databases from their inception to November 31, 2019, with no language restriction. The following search terms were used: (KIM1OR KIM-1 OR kidney injury molecule 1) AND (contrast OR radio contrast OR contrast media OR contrast medium \[CM\] OR radio-contrast media OR radio contrast medium OR contrast agent\] AND (acute kidney injury OR AKI OR acute kidney failure OR renal failure) AND (coronary angiography OR percutaneous coronary interventions OR cardiac catheterization). References of relevant studies were searched manually to identify eligible studies. In addition, abstracts were included in this meta-analysis if they contained complete results sections. The search was performed by two investigators (QL and YH).

2.2. Study Selection {#sec2.2}
--------------------

Studies were assessed and selected based on titles and abstracts by two independent reviewers; conflicts were resolved by a third reviewer (YL). The inclusion criteria were as follows:uKIM-1 was used as a biomarker to diagnose CI-AKI after PCI or CAG.The study should be observational.uKIM-1 concentration values for true-positive, false-negative, false-positive, and true-negative were provided or could be calculated to predict CI-AKI.

The exclusion criteria were as follows:Review articles or duplicate papersAnimal or in vitro based studiesStudies that did not provide the diagnostic accuracy of uKIM-1

2.3. Data Extraction and Study Quality Assessment {#sec2.3}
-------------------------------------------------

After a detailed full-text review of each study, data was extracted from the retained studies by two independent reviewers (QL and YH). Disagreements were resolved by discussion and assessed by a third reviewer (YL) until a consensus was reached. The following data were extracted from the included studies for analysis: first author, year of publication, original country, sample size, study design, incidence of CI-AKI, inclusion renal criteria, patient characteristics (age, sex, baseline serum creatinine, and the proportion of patients with hypertension and diabetes mellitus), definition of CI-AKI, and CM (contrast media) type. Information about biological material, measurement assay, and time of uKIM-1 management was also collected. In addition, sensitivity and specificity from the cutoff value of the uKIM-1 level predicting CI-AKI (obtained by receiver operating characteristic (ROC) analysis and the area under the curve (AUC) of ROC) were extracted from the studies.

The methodological quality of each included study was assessed by two independent reviewers (QL and YH) who used the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool \[[@B12]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analyses were performed using STATA version 14.0 (Stata Corp, College Station, TX), notably with the "midas" commands \[[@B13]\]. An exact binomial rendition of the bivariate mixed-effects regression model that was developed by von Houwelingen et al. \[[@B14]\] for meta-analysis of treatment trials and modified for diagnostic test data using an approximate normal within study model was used \[[@B15]\]. The bivariate mixed-effects model fits a 2-level model, with independent binomial distributions for the true positives and true negatives conditional on the sensitivity and specificity in each study, and a bivariate normal model for the logit transformations of sensitivity and specificity between studies \[[@B13]\]. Based on this model, the pooled sensitivity (SEN), pooled specificity (SPE), positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio (DOR) with their 95% CIs were obtained. We also constructed hierarchical summary ROC curves to plot sensitivity versus specificity and calculated the AUC \[[@B16]\]. The degree of the heterogeneity, which indicates the variation of included studies, was assessed using the *I*^2^ statistic \[[@B15]\]. I^2^ describes the percentage of total variation across studies that is attributable to the heterogeneity rather than to chance. The value of *I*^2^ lies between 0% and 100%, a value of 0% indicates no observed heterogeneity, and values greater than 50% may be considered substantial heterogeneity \[[@B13]\]. In addition, we conducted a subgroup analysis according to the detection time, sample size, and presence of chronic kidney disease. Publication bias was evaluated using Deek\'s effective sample size funnel plot.

3. Results {#sec3}
==========

3.1. Study Selection {#sec3.1}
--------------------

The study selection process is shown in [Figure 1](#fig1){ref-type="fig"}. A total of 1116 publications from different databases were retrieved upon initial search. Of those, 657 articles were excluded due to duplication. The remaining studies were screened by title and/or abstract; 441 of them were removed because they were reviews, animal research, or conference abstracts. Of the remaining 18 studies, 9 were excluded due to missing essential data (e.g., SEN, SPE, and diagnostic criteria used). In addition, one article \[[@B17]\] was found during the manual review of the references of a review article \[[@B1]\] and included in this meta-analysis. In summary, 9 original studies \[[@B8]--[@B10], [@B17]--[@B22]\] were included in this meta-analysis.

3.2. Study Characteristics {#sec3.2}
--------------------------

All studies were single-center trials that had their findings published between 2013 and 2017. Of the included studies, 7 were published in English \[[@B8]--[@B10], [@B17]--[@B19], [@B22]\], and 2 were published in Chinese \[[@B20], [@B21]\]. The 9 studies included a total of 946 adult patients from 5 countries who underwent PCI or GAC, and 144 were diagnosed as CI-AKI. Among these studies, 8 included patients with normal sCr levels and 1 \[[@B10]\] included CKD patients. Patients treated with dialysis or who used renal toxic drugs were excluded from all studies. However, the definition of CI-AKI differed among the studies. Six of the studies used a traditional definition for CI-AKI (increase in SCr ≥ 0.5 mg/dL or ≥ 25% within 48--72 hours after contrast exposure) \[[@B4]\], while three studies did not \[[@B8], [@B17], [@B19]\]. The characteristics of all the individual studies are listed in [Table 1](#tab1){ref-type="table"}.

3.3. Methodological Quality of Included Studies {#sec3.3}
-----------------------------------------------

The methodological quality assessment for the studies included in this meta-analysis is shown in [Table S1](#supplementary-material-1){ref-type="supplementary-material"}. The overall quality of the eligible studies was not robust. Most studies showed low risk in the domain of patient selection, while three studies \[[@B8], [@B18], [@B20]\] that did not avoid a case-control design showed high risk. An unclear risk was shown in the domain of index test since most of the studies did not indicate if a threshold was used. An unclear risk was also shown in the domain of risk of bias because information about whether reference standard results were interpreted without knowledge of the results of the index test was not provided in most studies. There was high risk in the domain of flow and timing because two studies \[[@B10], [@B20]\] did not include all the patients in the analysis. All the studies were regarded to be of low risk for concerns regarding applicability.

3.4. Result of Individual Studies {#sec3.4}
---------------------------------

The performance of uKIM-1 concentrations for predicting CI-AKI has been summarized in [Table 2](#tab2){ref-type="table"}. Urinary KIM-1 levels were measured in all of the studies. Enzyme-linked immunosorbent assay (ELISA) was used in all of the studies to evaluate the level of uKIM-1. The time of the uKIM-1 test ranged from 6 to 24 hours after PCI or GAC. The cutoff value of the uKIM-1 level used to predict CI-AKI varied from 0.048 to 6.33 ng/ml, and one study even set the cutoff value as 3 times of the baseline uKIM-1. Moreover, the AUC of uKIM-1 for predicting CI-AKI ranged from 0.713 to 0.95.

3.5. Meta-Analysis {#sec3.5}
------------------

As shown in [Figure 2](#fig2){ref-type="fig"}, the pooled sensitivity and specificity of all studies was 0.84 (95% CI 0.76--0.90) and 0.78 (95% CI 0.71--0.84), respectively. *I*^2^ was 37.73 for the summary sensitivity and 69.31 for the summary specificity, suggesting a substantial heterogeneity in the sample of studies. The area under the receiver operating characteristic curve (AUROC) was 0.88 (95% CI 0.84--0.90). The SROC graph with the 95% confidence region and the 95% prediction region are shown in [Figure 3](#fig3){ref-type="fig"}.

A subgroup analysis was performed to explore potential sources of heterogeneity among studies. As shown in [Table 3](#tab3){ref-type="table"}, the diagnostic accuracy of uKIM-1 was higher in test time of \<24 hour group than test time at 24 hour group. However, the opposite findings were found in the subgroups with CKD and large sample sizes.

The result of the Deek\'s funnel plot asymmetry test with a superimposed regression line is shown in [Figure 4](#fig4){ref-type="fig"}. The *P* value for the slope coefficient was 0.12, indicating nonsignificant asymmetry. This result indicates no potential publication bias among studies.

4. Discussion {#sec4}
=============

In recent years, the gold standard for AKI diagnosis, the concentration of serum creatinine, has showed many limitations. Thus, several new biomarkers for early detection of AKI have been studied. Among them, the most promising are neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1).

KIM-1 is a phosphatidylserine receptor and expressed in epithelial cells. It can recognize and phagocytose dead cells that are present in the stressed kidney \[[@B5]\]. In normal situations, KIM-1 is undetectable in urine. But when the proximal tubule suffers from ischemic or toxic injury, the ectodomain of KIM-1 is shed into the urine of humans \[[@B6], [@B7]\]. As a result, it is possible to use urinary KIM-1 (uKIM-1) to predict tubular injury and AKI.

A number of clinical studies have reported the excellent diagnostic value of uKIM-1 level for AKI caused by different reasons and in different populations \[[@B23]--[@B25]\]. The findings from a meta-analysis evaluating the predictive value of uKIM-1 in the setting of AKI, which included 2979 patients from 11 studies, suggest it is an efficacious diagnostic marker for AKI \[[@B11]\]. However, AKI caused by use of imaging contrast has not been systematically assessed to date. Thus, we performed a systematic and comprehensive review to investigate the diagnostic value of uKIM-1 for early detection of CI-AKI in patients who undergo PCI or CAG. To our knowledge, this is the first meta-analysis performed to evaluate the ability of uKIM-1 to predict CI-AKI.

Although we tried our best to search for all the eligible studies, there were only 9 that met our inclusion criteria and were included in the meta-analysis. Fortunately, these 9 studies showed a considerate homogeneity, indicating that the pooled results in this meta-analysis were reliable and stable.

In our study, SEN, SPE, and AUC were used for indicating the performance of uKIM-1 for CI-AKI prediction; all the studies showed that uKIM-1 was a good predictor. The AUC values were above 0.70 for all studies (in fact, two studies reported an AUC \>0.90(18, 22)). Moreover, the pooled AUC (0.88, 95% CI 0.85--0.90) also indicates a considerable value in using uKIM-1 for the diagnosis of CI-AKI. Ho et al. constructed a meta-analysis of using uKIM-1 for diagnosis of AKI associated with cardiac surgery \[[@B26]\]. In this meta-analysis, the AUC of uKIM-1 for intraoperative and postoperative AKI were 0.68 (0.58--0.78) and 0.72 (0.69--0.84), respectively. There was also a meta-analysis carried out by Wang et al. that assessed the predictive value of NGAL for CI-AKI and showed an AUC of 0.93 \[[@B27]\]. In comparison with the aforementioned findings, we ascertained that uKIM-1 was much more effective for the diagnosis of CI-AKI than for cardiac surgery associated AKI but less powerful than NGAL for predicting CI-AKI.

Urinary KIM-1 was reported to be influenced by detection time. In a cohort of 103 adults undergoing cardiopulmonary bypass (CPB), the uKIM-1 levels increased by approximately 40% at 2 hours postoperatively and by more than 100% at the 24-hour time point \[[@B28]\]. In a nested case-control study consisting of cardiac catheterization patients, uKIM-1 increased 6 hours after contrast from the baseline and peaked at 24 hours, suggesting it may perform well in the relatively late time period (rather than at 6 hours) after AKI (19). We also found that 24-hour postcontrast exposure time was the best detecting point for uKIM-1. We stratified the included studies based on test times, 24 hours (detected uKIM-1 24 hours after contrast exposure), and \<24 hours group (detected uKIM-1 24 hours before contrast exposure) and noticed that the values of AUC in 24 hour group were higher than those of the under 24 hours group. One of these studies detected uKIM-1 at both 6 hours and 24 hours after contrast and reported an AUC of 0.74 (95% CI 0.49--0.91, *P*=0.0064) and 0.85 (95% CI 0.72--0.95, *p*0.002), respectively. Another study \[[@B18]\] also illustrated that it is better to detect KIM-1 at 24 hours after contrast exposure. However, a study by Han et al. \[[@B29]\] showed that uKIM-1 levels did not rise significantly in patients of contrast-induced nephropathy. These mixed findings might be explained by differences in the renal inclusion criteria, inconsistent timing of urinary collections, and variable measurement methods.

Most of the included studies did not include patients with CKD, except for the study conducted by Wang et al. \[[@B10]\]. The results of the sensitivity analysis show that exclusion of CKD increased the stability of sensitivity. This indicates that the accuracy of uKIM-1 for predicting CI-AKI differs between patients with and without CKD. AKI that happened on CKD patients is known to be severe and different to recover \[[@B30]\]. The pathophysiological changes of CKD, such as the activation of TGF-*β*, p53, and HIF pathways in kidney and CKD related chronic inflammation and vascular dysfunction, might contribute to the severe AKI progress \[[@B30]\]. On the contrary, some clinical studies found that KIM-1 did not provide robust prognostic information on the loss or renal function in CKD population \[[@B31], [@B32]\]. Since the sample size was small in Wang et al. \[[@B10]\] research, studies with a larger sample size are needed to clarify this problem.

Recently, similar meta-analysis studies were done on the predictive value of KIM-1 in predicting AKI in different populations. However, the diagnostic value of KIM-1 varied. In a meta-analysis included general population, KIM-1 was found to be a promising biomarker for AKI prediction with an AUC of 0.86 \[[@B11]\]. In another study which only enrolled children, KIM-1 (AUC = 0.69) is not recommended for AKI diagnosis \[[@B33]\]. Those conflicted conclusions show that the diagnostic power of KIM-1might not be consistent in people of different ages. Further, KIM-1 only showed modest discrimination in diagnosing AKI in cardiac surgery patients \[[@B26]\] and showed stronger diagnostic power in our studies with patients received cardiac catherization treatment, since contrast is the main cause of AKI after cardiac catherization \[[@B34]\], while ischemia contributes to AKI after cardiac surgery in most cases \[[@B35]\]. The difference in pathophysiological mechanisms in these two conditions might lead to the discrepancy in KIM-1 diagnostic value on AKI.

5. Limitations {#sec5}
==============

Limitations of this meta-analysis include the small number of studies included. Also, it was hard to assess influence of detecting time, as most studies detected uKIM-1 at different times but only one study reported the complete data. A few studies tested more than one biomarker; however, the details for the combined diagnosis of uKIM-1 and other biomarkers were not reported. Moreover, patients with different renal function and age were not accounted for (or controlled for) in most of the study designs.

6. Conclusion {#sec6}
=============

The findings from this meta-analysis demonstrate that uKIM-1 is a relatively good biomarker for prediction CI-AKI in patients who undergo PCI or CAG. The optimal detection time is 24 hours after contrast exposure, suggesting that uKIM-1 can predict CI-AKI at an earlier time than sCr. Clinical studies with large sample sizes are needed to further explore the diagnostic ability and prognostic value of uKIM-1 in different populations (e.g., different age, renal function, and comorbidities).
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![Flow diagram for the review process and outcomes of inclusion and exclusion.](JITC2020-4982987.001){#fig1}

![Forrest plots of the sensitivity and specificity of each individual study, summary sensitivity and specificity, and I^2^ statistic for heterogeneity.](JITC2020-4982987.002){#fig2}

![Summary receiver operating characteristic (SROC) graph with 95% confidence region and 95% prediction region for the diagnosis value of CI-AKI by KIM-1.](JITC2020-4982987.003){#fig3}

![Deek\'s funnel plot asymmetry test.](JITC2020-4982987.004){#fig4}

###### 

Characteristics of included studies.

  Author, country, year                        Sample size   Study design          CI-AKI patients number   Inclusion criteria                                    Age, years N/C            Male N/C            SCr baseline N/C mmol/L        CI-AKI criteria                                                                                                                                                      Hypertension % N/C   DM% N/C      CM type
  -------------------------------------------- ------------- --------------------- ------------------------ ----------------------------------------------------- ------------------------- ------------------- ------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------ ----------------------------------------------------------
  Wybraniec et al., Poland, 2017 \[[@B22]\]    95            Prospective           9                        Normal sCr                                            64 (52--75)               52 (54.4%)          70.72 (60.99--82.21)           ≥50% relative or ≥0.3 mg/dL absolute increase of serum creatinine concentration at 48 h postprocedurally                                                             48 (50.4%)           17 (17.6%)   Iopromide (LOCM) or Iodixanol (IOCM) or Iomeprol (LOCM)
  Akdeniz et al., Turkey, 2015 \[[@B8]\]       52            Nested case-control   32                       Normal sCr                                            67.5 ± 10.1/61.6 ± 9.4    11(34.4)/12(60.0)   79.56(44.2--167.96)            An increase in sCr by 0.3 mg/dL from a baseline level according to the KDIGO 2012 AKI criteria                                                                       -/0.5                81.3/85      Iodixanol
  Li et al., China, 2015 \[[@B9]\]             145           Prospective           19                       eGFR \> 15 mL/min/1.73 m^2^                           66.8 ± 9.9                91(62.8)            70.58 ± 9.9/60.41 ± 14.20      An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24--48 h after the intravascular injection of contrast medium, without an alternative etiology     NR                   NR           Nonionic, low osmolarity contrast agent
  Luo et al., China, 2013 \[[@B18]\]           42            Nested case-control   12                       sCr \< 1.5 mg/dL in male/sCr \< 1.2 mg/L in female    68.4 ± 10.1/64.7 ± 13.2   5(41.7)/12(40.0)    68.76 ± 10.92/66.57 ± 12.89    An absolute rise in sCr of ≥0.5 mg/dl (44.2 mmol/l), and/or *a* ≥25% increase from the baseline within 48 hours                                                      58.3/56.7            NR           Nonionic, low osmolarity contrast medium (iopamidol)
  Torregrosa et al., Spain, 2015 \[[@B19]\]    144           Prospective           20                       eGFR \> 15 mL/min/1.73 m^2^                           72 ± 10/62 ± 13           16(75)/94(75.8)     78.68 ± 21.22/100.78 ± 23.87   An increase in sCr ≥ 50 % according to the RIFLE classification system                                                                                               NR                   NR           NR
  Vijayasimha et al., India, 2014 \[[@B17]\]   100           Prospective           12                       sCr \< 1.5 mg/dL in male/sCr \< 1.2 mg/Ll in female   48.6 ± 11                 62(62)              106.09 ± 15.03                 An increase in sCr \>25% of the baseline level 48 hours after contrast                                                                                               NR                   NR           Low osmolarity contrast (iodizanol or iopromide) medium.
  Wang et al., China, 2014 \[[@B10]\]          42            Prospective           14                       eGFR \>15 mL/min/1.73 m^2^                            60.2 ± 9.5/60.6 ± 8.1     7(50)/16(57)        82.2 ± 18.3/92.0 ± 15.5        An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24--48 h after the intra- vascular injection of contrast medium, without an alternative etiology   64/60                14/17        A nonionic, low osmolarity contrast agent 844 mOsm/kg
  Wang, China, 2013 \[[@B21]\]                 260           Prospective           20                       sCr \< 300 mmol/L                                     73.6 ± 8.9/60 ± 7.5       8(40)/135(56.3)     71.31 ± 8.3/65.7 ± 10.3        An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24--48 h after the intravascular injection of contrast medium, without an alternative etiology     50/20                15/5         a nonionic, low osmolarity contrast agent 600 mOsm/kg
  Wang, China, 2014 \[[@B20]\]                 66            Prospective           6                        eGFR \< 60 mL/min/1.73 m^2^                           NR                        NR                  NR                             An increase of ≥0.5 mg/dl or ≥25% in SCr levels over the baseline 24--48 h after the intravascular injection of contrast medium, without an alternative etiology     NR                   NR           NR

###### 

Performance of KIM-1 for CIN or CI-AKI diagnosis in the meta-analysis.

  Nr.   Author                          TP   FP   FN   TN    Total   Test time, hours   AUC      95% CI         SEN, %   SPE, %   Cutoff, ng/ml          Biological material   Assay
  ----- ------------------------------- ---- ---- ---- ----- ------- ------------------ -------- -------------- -------- -------- ---------------------- --------------------- -------
  1     Wybraniec et al. \[[@B22]\]     7    15   2    71    95      6h                 0.0081   NR             0.778    0.824    \>0.425                Urine                 ELISA
  2     Akdeniz et al. \[[@B8]\]        24   5    8    15    52      6                  0.797    0.677--0.917   75       75       3.66                   Urine                 ELISA
  3     Li et al. \[[@B9]\]             14   18   5    108   169     24                 0.854    0.782--0.929   73.7     85.7     6.327755               Urine                 ELISA
  4     Luo et al. \[[@B18]\]           10   4    2    26    42      24                 0.85     0.72--0.95     83       87       0.74                   Urine                 ELISA
  5     Torregrosa et al. \[[@B19]\]    14   45   6    79    144     12                 0.713    0.551--0.876   71.6     64       1.73                   Urine                 ELISA
  6     Wang and Pu \[[@B20]\]          12   8    2    20    42      24                 0.839    0.095--0.948   85.7     71.4     4.495                  Urine                 ELISA
  7     Wang \[[@B21]\]                 17   60   3    180   260     12                 0.903    0.802--0.100   85       75       0.0478425              Urine                 ELISA
  8     Wang et al. \[[@B10]\]          59   1    3    3     66      12                 0.742    NR             95.2     75       3^*∗*^KIM-1 baseline   Urine                 ELISA
  9     Vijayasimha et al. \[[@B17]\]   11   17   1    71    100     24                 0.95     NR             89       81       4.5                    Urine                 ELISA

###### 

Subgroup analysis.

  Subgroup              *N*   Sensitivity        Specificity         DOR           AUC
  --------------------- ----- ------------------ ------------------- ------------- -------------------
  *Test time \< 24 h*                                                               
  \<24 h                5     0.84(0.70, 0.93)   0.72 (0.64, 0.79)   15 (5, 42)    0.81 (0.77--0.84)
  24 h                  4     0.83(0.70, 0.91)   0.83 (0.77, 0.87)   23 (11, 49)   0.89 (0.86--0.91)
  ckd                                                                               
  No                    8     0.79 (0.71,0.86)   0.77 (0.70,0.83)    13 (7,24)     0.83 (0.80--0.86)
  Yes                   1     95.2               75                                0.742
                                                                                   
  *Large sample size*                                                               
  ≤100                  4     0.79 (0.68,0.87)   0.77 (0.68,0.84)    13 (6,29)     0.84 (0.80--0.87)
  \>100                 5     0.87 (0.75,0.94)   0.78 (0.67,0.86)    24 (9,69)     0.80 (0.76--0.83)

[^1]: Academic Editor: Salvatore De Rosa
